Esperion Therapeutics (ESPR) said Wednesday it has completed a series of financing agreements to repay a part of its current $265 million convertible debt facility.
The company said it obtained a $150 million senior term loan led by funds managed by Athyrium Capital Management and joined by funds managed by HealthCare Royalty. Esperion added that it also issued new $100 million convertible notes to accredited investors.
The new notes will mature on June 15, 2030, and will bear a semiannual interest payment, the company said.
Esperion said it intends to use the loan proceeds and roughly $60 million of the proceeds from the new notes to repay $210 million of the current convertible debt, while the remaining $40 million of the proceeds would be allocated as operating cash.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。